Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s32687
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
2017English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Stressful Events Increase Exacerbations in Relapsing-Remitting Multiple Sclerosis

BMJ
2003English

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Archives of Neurology
1999English

Cerebrovascular Reactivity and Disease Activity in Relapsing-Remitting Multiple Sclerosis

Advances in Clinical and Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

Alemtuzumab in the Long-Term Treatment of Relapsing-Remitting Multiple Sclerosis: An Update on the Clinical Trial Evidence and Data From the Real World

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy